Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Results of the primary end-point of the LOC-R01: A randomized phase II Study of lenalidomide and ibrutinib in association with rituximab-methotrexate procarbazine vincristin (R-MPV) as a targeted induction treatment for patients aged 18 to 65 with a newly diagnosed primary central nervous system lymphoma (PCNSL)

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCarole SoussainCHCaroline HouillierJHJessica Haddad

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved complete response rates in immunocompetent patients with PCNSL, indicating potential of targeted induction therapy.

Key Points

  • To evaluate the efficacy of lenalidomide or ibrutinib combined with R-MPV in newly diagnosed PCNSL patients.
  • Randomized phase II trial involving immunocompetent patients aged 18-65 with untreated PCNSL.
  • Patients received 4 cycles of R-MPV with either lenalidomide or ibrutinib.
  • Assessments were conducted based on IPCG criteria after MRI central review.
  • 86% complete response rate in lenalidomide arm and 82% in ibrutinib arm at induction phase.
  • Both treatment arms proceeded to autologous stem cell transplantation in significant numbers.
  • Safety profiles were consistent with the R-MPV regimen and targeted therapies.

Cite This Study

Soussain et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236cfd3https://doi.org/10.1182/blood-2025-58
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ibrutinib in combination with rituximab, methotrexate (MTX), vincristine, and procarbazine (R-MPV/i) for newly diagnosed primary CNS lymphoma (PCNSL)2025 · 1 citations
  2. 2Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up2025 · 2 citations
  3. 3Lenalidomide–rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach2025 · 1 citations
  4. 4Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma2025
  5. 5Orelabrutinib, rituximab, and thiotepa (ORT) in combination with or without high-dose methotrexate in untreated primary central nervous system lymphoma2025